Felix Osawaru
Psychiatric/Mental Health · Buffalo, NYNPI 1083229538
Payments from drug & device makers
Across 179 payments — averaging $28.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$842
- Alkermes, Inc.$820
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$668
- Otsuka America Pharmaceutical, Inc.$386
- AbbVie$328
- plus $889 from 7 others
What the payments were for
- Travel & lodging$3146%
- Food & beverage$4,79193%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 30 | $1,220 |
| Neurocrine Biosciences, Inc. | 13 | $842 |
| Alkermes, Inc. | 38 | $820 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $668 |
| Otsuka America Pharmaceutical, Inc. | 15 | $386 |
| AbbVie | 15 | $328 |
| Teva Pharmaceuticals USA, Inc. | 7 | $313 |
| Lundbeck LLC | 16 | $259 |
| E.r. Squibb & Sons, L.L.C. | 2 | $214 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Braeburn Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,416
- INGREZZA$624
- ARISTADA$413
- SPRAVATO$385
- COBENFY$122
- Austedo XR$117
- AUSTEDO$116
- CAPLYTA$112
- REXULTI$108
- INVEGA SUSTENNA$106
- ARISTADA INITIO$103
How this compares
$5,152 in reported general payments places this provider in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $170,992 |
| Invega TrinzaPaliperidone Palmitate | 12 | $128,864 |
| Invega SustennaPaliperidone Palmitate | 37 | $125,649 |
| Austedo XrDeutetrabenazine | 14 | $87,151 |
| Risperdal ConstaRisperidone Microspheres | 40 | $50,967 |
| RexultiBrexpiprazole | 33 | $49,845 |
| VraylarCariprazine Hcl | 31 | $44,836 |
| Abilify MaintenaAripiprazole | 14 | $40,776 |
| AristadaAripiprazole Lauroxil | 12 | $39,135 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $27,228 |
| CaplytaLumateperone Tosylate | 16 | $25,510 |
| SpravatoEsketamine Hcl | 26 | $24,894 |
| OzempicSemaglutide | 12 | $11,678 |
| TrintellixVortioxetine Hydrobromide | 19 | $8,899 |
| Aripiprazole | 162 | $7,320 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Risperdal Consta, Spravato | $1,220 | $330,374115 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $842 | $170,99220 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $386 | $90,62147 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $313 | $87,15114 claims |
| Alkermes, Inc.Aristada, Lybalvi | $820 | $66,36327 claims |
| AbbVieVraylar | $328 | $44,83631 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $668 | $25,51016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,385 psychiatric/mental health providers in New York.
Other psychiatric/mental health in Buffalo
- Carl de FrancoBuffalo$28K
- Sarah OtwellBuffalo$15K
- Tisha TanyiBuffalo$10K
- Richard ZawislakBuffalo$10K
- Glenn HannDansville$1.3M
- Tammy RussoNiskayuna$568K
- Carrie EdickSchenectady$484K
- Eric SpronzCentereach$448K
- Terry Jo Brooks-DevlinTonawanda$176K
- Kevin SiewersStaten Island$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.